Comparative Pharmacology
Head-to-head clinical analysis: REGROTON versus SER A GEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REGROTON versus SER A GEN.
REGROTON vs SER-A-GEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.
1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.
500 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 9-11 hours (mean 10 hours); clinical context: supports once-daily dosing in hypertension, steady-state reached in 3-4 days
8 ± 2 hours; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70-80% (50% as unchanged drug, 20-30% as metabolites); Fecal: <5%
Primarily renal: 70% unchanged drug; 20% as glucuronide conjugate; <5% fecal.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination